NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/06/2022
Voltar para busca
Dado oficial do USPTO
IGEG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
IGEG
ST13
US500000090424617Classe
5, 42, 44, 45
Pedido
90424617
Registro
6750023
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
23
Atualização mais recente
10/06/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44, 45
Data de depósito
29/12/2020
Data de registro
07/06/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
07/06/2022
Última transação
10/06/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
EINSTEIN, MATTHEW T
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Epsilogen Ltd
Representantes
Susan Piascik Christoff COOLEY LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing agents; immunostimulants; medicine for the treatment of cancer; diagnostic reagents for medical laboratory use
Classe 42
Development of platform technologycancer immunotherapy platforms for manufacturing therapeutics; research and development of pharmaceuticals in the fields of oncologyimmunology and immuno-oncology; research and development of pharmaceuticals for the treatment of cancer and oncological conditions; research and development in the field of cancer therapeuticsoncologynanoparticlestargeted therapies; research and development in the field of recombinant proteins and antibodies for therapeutic and prophylactic use; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new therapeutic proteins and antibodies; development of pharmaceuticalspharmaceutical ingredientsantibodies; scientific study and research in the field of developing personal scientific treatment strategies for patients with diagnosed cancer; pharmaceutical servicesdeveloping tumor targeting platform technologies; scientific research in the nature of scientific collection of specific molecular and genomic data for analytical and clinical purposesfor the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing medical and scientific research information in the field of pharmaceuticals and clinical trials in the fields of oncologyimmunology and immuno-oncology; pharmaceutical product development and evaluation services; pharmaceutical research and development; technical research in the field of pharmaceutical studies; conducting early evaluations in the field of new pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services in the fields of biotechnology and pharmaceutical research; consulting services for others in the field of designplanningimplementation of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Classe 44
Medical screening; medical monitoringtestinginspection and analysis services; medical services relating to the diagnosis and treatment of cancerous diseases; pharmaceutical advisory services; medical laboratory analysis services relating to the treatment of persons; medical laboratory analysis services relating to the diagnosis and treatment of cancerous diseases; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis; medical services in the field of oncologyimmunology and immuno-oncology; providing advice relating to oncologyimmunology and immuno-oncology; providing on-line information relating to oncologyimmunology and immuno-oncology
Classe 45
Licensing of intellectual property rights; licensing of industrial property rights
Publicações
Histórico de despachos e eventos da marca no USPTO.
23 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
07/06/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
29/04/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/04/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/02/2022
PUBO
PUBLISHED FOR OPPOSITION
15/02/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/01/2022
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/01/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
10/01/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/01/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
10/01/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
28/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/12/2021
ALIE
ASSIGNED TO LIE
23/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/06/2021
GNRT
NON-FINAL ACTION E-MAILED
28/06/2021
CNRT
NON-FINAL ACTION WRITTEN
28/06/2021
DOCK
ASSIGNED TO EXAMINER
28/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/03/2021
NWAP
NEW APPLICATION ENTERED
01/01/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace IGEG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.